Optimizing First-Line Therapy for Advanced-Stage Classic Hodgkin Lymphoma
Search for other papers by Ranjana H. Advani in
Current site
Google Scholar
PubMed
Goals of first-line therapy in classic Hodgkin lymphoma (cHL) should focus on balancing risk versus benefit to the individual while increasing efficacy and decreasing toxicity. Overall, the ABVD regimen is well tolerated but slightly less effective, with a better safety profile compared with escalated BEACOPP. BV-AVD is somewhere in between ABVD and escalated BEACOPP on the cure/morbidity scale. Interim PET is predictive, but new prognostic biomarkers are emerging that may better identify patients at high risk for treatment failure. In patients with interim PET-negative cHL, de-escalating therapy does not impact overall survival along 1) with no proven role for radiotherapy. cHL is largely a disease of young people, and the choice of treatment should always take into account the potential for both short- and long-term toxicity with the goal of optimizing survivorship.
Disclosures: Dr. Advani has disclosed receiving consulting fees from Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Inc., Gilead Sciences, Inc., Incyte Corporation, Roche Laboratories, Inc., and sanofi-aventis U.S.; and receiving grant/research support from Cytier Therapeutics, Forty Seven, Inc., Janssen Pharmaceutica Products, LP, Kura Oncology, Inc., Merck & Co., Inc., Millennium Pharmaceuticals, Inc., Pharmacyclics, Regeneron Pharmaceuticals, Inc., and Seattle Genetics, Inc.
© 2019-2024 National Comprehensive Cancer Network